Correction: Jazz Pharmaceuticals initiates Erwinaze trial, says Brean Capital Jazz announced initiated its new clinical trial for Erwinaze with will evaluate intravenous administration in patients with ALL as an alternative to intramuscular injection. Brean Murray maintains its estimates but believes there could be upside to its 2014 forecast. Shares are Buy rated with an $81 price target.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Allergan merger deal not imminent, CNBC's Faber reports An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.